SG11202000424VA - Peptide derivative and pharmaceutical composition containing same - Google Patents

Peptide derivative and pharmaceutical composition containing same

Info

Publication number
SG11202000424VA
SG11202000424VA SG11202000424VA SG11202000424VA SG11202000424VA SG 11202000424V A SG11202000424V A SG 11202000424VA SG 11202000424V A SG11202000424V A SG 11202000424VA SG 11202000424V A SG11202000424V A SG 11202000424VA SG 11202000424V A SG11202000424V A SG 11202000424VA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
composition containing
peptide derivative
containing same
peptide
Prior art date
Application number
SG11202000424VA
Other languages
English (en)
Inventor
Toyomasa Katagiri
Tetsuro Yoshimaru
Takashi Miyamoto
Yasuhide Okamoto
Original Assignee
Univ Tokushima
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokushima, Oncotherapy Science Inc filed Critical Univ Tokushima
Publication of SG11202000424VA publication Critical patent/SG11202000424VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202000424VA 2017-07-19 2018-07-18 Peptide derivative and pharmaceutical composition containing same SG11202000424VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017140101 2017-07-19
PCT/JP2018/026904 WO2019017384A1 (fr) 2017-07-19 2018-07-18 Dérivé peptidique et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
SG11202000424VA true SG11202000424VA (en) 2020-02-27

Family

ID=65015780

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000424VA SG11202000424VA (en) 2017-07-19 2018-07-18 Peptide derivative and pharmaceutical composition containing same

Country Status (10)

Country Link
US (1) US11091517B2 (fr)
EP (1) EP3656783A4 (fr)
JP (1) JP7291327B2 (fr)
KR (1) KR102658844B1 (fr)
CN (1) CN111148752B (fr)
AU (1) AU2018302855B2 (fr)
CA (1) CA3070210A1 (fr)
IL (1) IL272080A (fr)
SG (1) SG11202000424VA (fr)
WO (1) WO2019017384A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285604A (zh) * 2023-07-22 2023-12-26 湖南中晟全肽生化有限公司 一种对三阴性乳腺癌细胞具有抑制活性的多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP4647456B2 (ja) 2005-10-11 2011-03-09 オンコセラピー・サイエンス株式会社 新規基質を用いたｔｔｋ活性抑制剤のスクリーニング方法
KR20090064378A (ko) 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 유방암 관련 유전자 및 폴리펩티드
ES2613808T3 (es) 2011-07-29 2017-05-26 Oncotherapy Science, Inc. Péptido derivado de ERAP1 y uso del mismo
US10227390B2 (en) * 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CN107921896A (zh) 2015-07-20 2018-04-17 沃尔沃建筑设备公司 可移动扶手组件
EP3406626A4 (fr) * 2016-01-19 2020-02-19 Tokushima University Peptide pour traitement du cancer, et composition pharmaceutique contenant celui-ci
JP6159432B1 (ja) 2016-02-08 2017-07-05 株式会社コロプラ プログラム及びコンピュータ

Also Published As

Publication number Publication date
AU2018302855B2 (en) 2022-08-18
AU2018302855A1 (en) 2020-02-06
JPWO2019017384A1 (ja) 2020-05-28
US11091517B2 (en) 2021-08-17
EP3656783A1 (fr) 2020-05-27
CA3070210A1 (fr) 2019-01-24
IL272080A (en) 2020-03-31
KR20200029567A (ko) 2020-03-18
CN111148752A (zh) 2020-05-12
KR102658844B1 (ko) 2024-04-17
CN111148752B (zh) 2024-01-16
WO2019017384A1 (fr) 2019-01-24
US20200255474A1 (en) 2020-08-13
JP7291327B2 (ja) 2023-06-15
EP3656783A4 (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
HK1257373A1 (zh) 雙功能蛋白質和包含其的藥物組合物
HK1259145A1 (zh) 3-脫氧衍生物及其藥物組合物
HK1251153A1 (zh) 一種藥物組合物及其應用
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986A (en) pharmaceutical preparation
HUE053354T2 (hu) Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények
GB201712159D0 (en) Pharmaceutical composition
ZA202004658B (en) Pharmaceutical composition comprising an apl type peptide
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
GB201719447D0 (en) Pharmaceutical composition
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
IL279877A (en) Ibusidanib forms and pharmaceutical preparations
EP3727485C0 (fr) Composition pharmaceutique
IL272080A (en) Derivation of a peptide and a pharmaceutical preparation containing it
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
SG11202010069SA (en) Dipeptide and pharmaceutical composition containing same
EP3718543A4 (fr) Composition pharmaceutique et son utilisation
EP3653626A4 (fr) Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
SG11202010046WA (en) Pharmaceutical composition containing dipeptide
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201812022D0 (en) Pharmaceutical methods and compositions
GB201708328D0 (en) Pharmaceutical composition
GB201708329D0 (en) Pharmaceutical composition
GB201705661D0 (en) Pharmaceutical composition